Levosimendan

• Description:

  Levosimendan (Simsndan; OR-1259) is a calcium sensitiser used in the management of acutely decompensated congestive heart failure.

• Product Name Alternative:

  Simsndan; OR-1259

• UNSPSC:

  12352005

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Autophagy; Phosphodiesterase (PDE) ; Potassium Channel

• Type:

  Reference compound

• Related Pathways:

  Autophagy; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/Levosimendan.html

• Purity:

  99.82

• Solubility:

  DMSO : ≥ 50 mg/mL

• Smiles:

  O=C1C[C@@H](C)C(C2=CC=C(N/N=C(C#N)/C#N)C=C2)=NN1

• Molecular Formula:

  C14H12N6O

• Molecular Weight:

  280.28

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Nieminen, M.S., et al., Levosimendan: current data, clinical use and future development. Heart Lung Vessel, 2013. 5 (4) : p. 227-245.|[2]Papp, Z., et al., Levosimendan: molecular mechanisms and clinical implications: consensus of experts on the mechanisms of action of levosimendan. Int J Cardiol, 2012. 159 (2) : p. 82-7.|[3]Landoni, G., et al., Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med, 2012. 40 (2) : p. 634-46.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• CAS Number:

  [141505-33-1]